Baader Bank Aktiengesellschaft Grows Holdings in Incyte Corporation $INCY

Baader Bank Aktiengesellschaft boosted its holdings in shares of Incyte Corporation (NASDAQ:INCY) by 100.2% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 12,642 shares of the biopharmaceutical company’s stock after purchasing an additional 6,326 shares during the period. Baader Bank Aktiengesellschaft’s holdings in Incyte were worth $1,072,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Wealthfront Advisers LLC raised its holdings in Incyte by 11.1% during the third quarter. Wealthfront Advisers LLC now owns 8,187 shares of the biopharmaceutical company’s stock worth $694,000 after purchasing an additional 821 shares in the last quarter. ProShare Advisors LLC increased its position in Incyte by 3.4% during the 3rd quarter. ProShare Advisors LLC now owns 45,179 shares of the biopharmaceutical company’s stock worth $3,832,000 after purchasing an additional 1,471 shares during the period. Linden Thomas Advisory Services LLC purchased a new position in shares of Incyte during the 3rd quarter worth approximately $222,000. RFG Advisory LLC acquired a new stake in shares of Incyte in the 3rd quarter valued at approximately $247,000. Finally, Fielder Capital Group LLC acquired a new stake in shares of Incyte in the 3rd quarter valued at approximately $211,000. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

INCY has been the subject of a number of research analyst reports. Morgan Stanley set a $102.00 target price on shares of Incyte in a report on Wednesday. Guggenheim upgraded shares of Incyte from a “neutral” rating to a “buy” rating and set a $125.00 price objective on the stock in a research report on Monday, November 3rd. Wall Street Zen raised shares of Incyte from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Mizuho set a $121.00 target price on shares of Incyte and gave the stock an “outperform” rating in a research report on Monday, December 8th. Finally, Wells Fargo & Company reduced their price target on shares of Incyte from $107.00 to $101.00 and set an “equal weight” rating on the stock in a report on Wednesday. Nine research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $103.94.

Incyte News Roundup

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Q4 revenue beat — Incyte reported $1.51B in Q4 sales (vs. ~$1.35B expected), reflecting 28% YoY growth driven by Jakafi and Opzelura; this supports near‑term top‑line momentum. Earnings Press Release
• Positive Sentiment: Earnings call emphasized pipeline beyond Jakafi — management highlighted growth drivers and progress on non‑Jakafi programs, which could ease long‑term reliance on the franchise. Earnings Call Transcript
• Positive Sentiment: HC Wainwright reiterates Buy with $135 target — a high‑conviction bullish call pointing to underappreciated pipeline value and long‑term revenue durability. HC Wainwright Buy Note
• Neutral Sentiment: Some voices argue the selloff is an overreaction to a guidance miss — analysis suggesting the weakness may be near‑term and that the stock could reprice if pipeline data and longer‑term growth prove resilient. Seeking Alpha: Overreaction
• Neutral Sentiment: Short‑interest reports in the feed show zero shares/NaN changes — data appears erroneous and should be treated with caution; no clear short squeeze signal. Article Title
• Negative Sentiment: EPS miss and weak 2026 revenue guide — Q4 EPS of $1.80 missed estimates (~$1.96) and management issued a soft full‑year net product revenue outlook, heightening concerns about replacing Jakafi sales as patents lapse. Reuters: Weak 2026 Forecast
• Negative Sentiment: Analyst downgrades/target cuts add pressure — Royal Bank of Canada cut its target to $92 (sector perform), signaling downside risk vs. current levels; other shops trimmed targets too. TickerReport: RBC Cut

Insider Buying and Selling at Incyte

In other Incyte news, EVP Michael James Morrissey sold 54,008 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $97.29, for a total transaction of $5,254,438.32. Following the transaction, the executive vice president owned 31,830 shares in the company, valued at $3,096,740.70. The trade was a 62.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Mohamed Khairie Issa sold 10,856 shares of the stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $109.07, for a total value of $1,184,063.92. Following the completion of the sale, the executive vice president owned 66,132 shares of the company’s stock, valued at approximately $7,213,017.24. This trade represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 95,225 shares of company stock worth $9,519,745. 17.80% of the stock is currently owned by insiders.

Incyte Price Performance

Shares of NASDAQ:INCY opened at $98.84 on Thursday. The company has a market cap of $19.40 billion, a P/E ratio of 15.42, a P/E/G ratio of 0.60 and a beta of 0.82. The business has a fifty day simple moving average of $101.75 and a 200-day simple moving average of $93.81. Incyte Corporation has a 52 week low of $53.56 and a 52 week high of $112.29. The company has a quick ratio of 3.13, a current ratio of 3.23 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.80 EPS for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). The firm had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.35 billion. Incyte had a return on equity of 26.34% and a net margin of 25.03%.The company’s quarterly revenue was up 27.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.43 earnings per share. Equities research analysts forecast that Incyte Corporation will post 4.86 EPS for the current year.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.